Kyprolis fails to beat Velcade in first-line MM combo study

Amgen Inc. (NASDAQ:AMGN) said a Kyprolis carfilzomib regimen missed the primary endpoint of significantly improving progression-free survival (PFS) over a Velcade bortezomib regimen in the Phase III CLARION trial to treat first-line multiple myeloma. The Kyprolis combo led to median PFS of 22.3 months vs. 22.1 months for the Velcade combo (HR=0.91, 95% CI: 0.75, 1.10). Both drugs were given along with melphalan and prednisone.

Amgen said data are not yet mature for the secondary endpoint of overall survival (OS). Early data show Velcade patients living longer than those receiving Kyprolis (observed HR=1.21; 95% CI: 0.90, 1.64). Neither survival outcome was statistically significant. ...